Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02331706 · ClinicalTrials.gov registry record · Early Phase 1
IFN-DLI for Relapsed Acute Leukemia After Allo-SCT
A Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 16
- Enrollment target
NCT02331706: Completed Early Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02331706 is a Early Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 16 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02331706, a Early Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This trial is designed to determine the feasibility of conventional induction chemotherapy, IFNand G-CSF mobilized DLI (IFN-DLI) in subjects with relapsed AML and ALL after allo-SCT.
Interventions
- DRUG Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-11-11 |
| Phase | Early Phase 1 |
What the finished NCT02331706 record still lists
NCT02331706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily is the first listed.
NCT02331706 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02331706 about?
NCT02331706 is a clinical study titled "IFN-DLI for Relapsed Acute Leukemia After Allo-SCT". This trial is designed to determine the feasibility of conventional induction chemotherapy, IFNand G-CSF mobilized DLI (IFN-DLI) in subjects with relapsed AML and ALL after allo-SCT.
What is the current status of trial NCT02331706?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 16 participants. The study started on 2014-12. Estimated completion is 2017-11-11.
What interventions are being tested in trial NCT02331706?
The interventions under investigation include: Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily (DRUG).
Who is sponsoring clinical trial NCT02331706?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02331706's enrollment target sits among peer trials
16 1370th of 2000 higher than 598 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia